A mutation is a change in genetic material. Modern clinical practice often uses the more neutral term genetic variant, because a change may be benign, protective or disease-causing. Mutations arise spontaneously during DNA replication or after environmental damage, and they may occur in germ cells, somatic tissues or both. Their consequences depend on location, size, gene function, zygosity, timing and the body’s DNA-repair systems.
At a glance
- Germline variant: present in an egg or sperm (or their precursors) and potentially transmitted to descendants.
- Somatic variant: acquired in body cells; usually not inherited by children but may drive cancer or mosaic disease.
- Point variant: a single-base change; may be synonymous, missense, nonsense or splice-altering.
- Indel: insertion or deletion; a frameshift can change every downstream codon.
- Loss-of-function, gain-of-function and dominant-negative describe functional consequences, not simply the size of a DNA change.
- A laboratory finding is not automatically pathogenic; classification requires population, computational, functional, segregation and clinical evidence.
Learning outcomes
The learner should be able to define mutation and variant, classify sequence and structural changes, explain spontaneous and induced causes, distinguish germline from somatic mosaicism, outline DNA-repair pathways, describe how mutations alter protein and cell behaviour, and interpret basic clinical and laboratory implications.
1. Terminology: mutation, variant and polymorphism
Mutation traditionally means a permanent change in DNA sequence. It remains useful in terms such as “mutation rate,” “driver mutation” and “mutation-induced disease,” but it can incorrectly imply harm. Variant is preferred when significance is unknown. A polymorphism is a variant common enough in a population to be considered a normal population difference; a common allele can still influence disease susceptibility or drug response.
Variants may be benign, likely benign, of uncertain significance, likely pathogenic or pathogenic. These categories describe current evidence, not a patient’s worth or destiny.
2. How mutations arise
2.1 Replication and proofreading errors
DNA polymerases copy billions of bases during cell division. A mispaired base may escape proofreading and become permanent after another replication cycle. Short repeated sequences are especially prone to polymerase slippage, producing small insertions, deletions or repeat expansions.
2.2 Spontaneous chemical changes
- Deamination: cytosine can deaminate to uracil; methylated cytosine can deaminate to thymine, creating common transition mutations.
- Depurination: loss of a purine leaves an abasic site that can be misread.
- Oxidative damage: reactive oxygen species modify bases such as guanine and create strand breaks.
- Replication stress: stalled forks can collapse or be repaired inaccurately.
2.3 Environmental and occupational mutagens
| Agent | Typical DNA damage | Clinical context |
|---|---|---|
| Ultraviolet radiation | Thymine dimers and nucleotide distortion | Skin cancer risk; photosensitive disorders |
| Ionising radiation | Single- and double-strand breaks | Radiotherapy, occupational or accidental exposure |
| Tobacco smoke components | DNA adducts, oxidative injury and strand damage | Multiple smoking-related cancers |
| Industrial chemicals and solvents | Adducts, cross-links or oxidative damage | Risk depends on agent, dose and duration |
| Some infectious agents | Chronic inflammation, insertional effects or viral oncogenes | HPV, hepatitis viruses and other cancer-associated infections |
Risk depends on dose, route, timing, metabolism, tissue susceptibility and protective measures. A suspected exposure does not prove that a particular mutation caused disease.
3. Types of genetic change
3.1 Single-nucleotide variants
A transition replaces a purine with a purine or a pyrimidine with a pyrimidine; a transversion exchanges the two classes. The same nucleotide change can be harmless in one location and pathogenic in another.
3.2 Insertions and deletions
An insertion or deletion of three bases (or a multiple of three) may add or remove amino acids without shifting the reading frame. A non-multiple-of-three change causes a frameshift and often introduces an early stop codon. Small indels can also alter promoters, splice sites or untranslated regions.
3.3 Repeat expansions
Trinucleotide and other repeat sequences can expand during gamete formation or early development. Some disorders show anticipation—earlier onset or greater severity in successive generations—although the pattern depends on the specific repeat and gene.
3.4 Copy-number and structural variants
- Deletions and duplications change gene dosage.
- Inversions can disrupt a gene or impair pairing during meiosis.
- Translocations can create gene fusions or regulatory changes.
- Large insertions, mobile-element insertions and complex rearrangements may be missed by routine sequencing.
4. Where the mutation occurs
4.1 Germline
A germline variant is present in the egg or sperm, or arises very early after fertilisation. It can be present in most cells and passed to children. A parent may be unaffected because of reduced penetrance, sex-dependent expression or a recessive genotype.
4.2 Somatic
Somatic variants arise after conception in body cells. They can create a clone of abnormal cells, contribute to cancer or produce segmental/mosaic disease. They are generally not transmitted to offspring, although a gonadal mosaic variant can be passed on despite being absent from blood.
4.3 Mosaicism
Mosaicism means two or more genetically different cell lines in one individual. The phenotype depends on the timing of the event, affected tissues, variant burden and selective advantage of the abnormal cells. A negative blood test does not exclude a tissue-limited mosaic condition.
5. Functional consequences
| Consequence | Mechanism | Example pattern |
|---|---|---|
| Loss-of-function | Reduced or absent protein activity | One normal allele may be enough, or disease appears when both are affected |
| Haploinsufficiency | One working copy cannot produce enough product | Often dominant dosage disorders |
| Gain-of-function | Increased, constitutive or new activity | Some receptor or signalling disorders |
| Dominant-negative | Abnormal protein interferes with the normal product | Structural multimeric proteins |
| Neomorphic | New biochemical function | Selected enzyme or signalling changes |
| Regulatory change | Altered timing, tissue or amount of expression | Enhancer or promoter variant |
5.1 Protein-level effects
- Synonymous: amino acid unchanged, but codon usage, splicing or RNA stability may be altered.
- Missense: amino acid substitution; effect depends on conservation, structure and biochemical properties.
- Nonsense: premature stop; transcript may be degraded or a truncated protein produced.
- Splice-altering: exon skipping, intron retention or cryptic splice-site use.
- Start-loss/stop-loss: translation starts incorrectly or continues beyond the normal stop.
6. DNA damage and repair
6.1 Proofreading and mismatch repair
Replicative polymerases correct many errors immediately. Mismatch-repair proteins detect remaining mispaired bases and correct the newly synthesised strand. Inherited mismatch-repair defects increase the risk of certain cancers.
6.2 Base-excision repair
DNA glycosylases remove damaged bases such as oxidised or deaminated nucleotides. Endonucleases, polymerase and ligase then restore the strand. This pathway handles small, non-bulky lesions.
6.3 Nucleotide-excision repair
Bulky, helix-distorting lesions such as UV-induced dimers are cut out as an oligonucleotide and replaced. Defects cause disorders with marked photosensitivity and skin-cancer risk.
6.4 Double-strand-break repair
- Homologous recombination: uses a matching template and is relatively accurate, especially after replication.
- Non-homologous end joining: directly rejoins ends and can introduce small insertions/deletions.
- Faulty repair may cause translocations, deletions, chromosomal instability and cancer.
When damage is too extensive, p53 and other checkpoints can pause the cell cycle, trigger senescence or activate apoptosis. Failure of these safeguards permits mutated clones to expand.
7. Mutations and cancer
Cancer usually develops through the accumulation of somatic driver variants in oncogenes, tumour-suppressor genes, DNA-repair genes and pathways controlling apoptosis or cell division. Passenger variants are present but do not drive growth. A germline predisposition increases risk; a tumour still usually needs additional somatic changes.
- Oncogene activation: a normal growth-promoting gene becomes overactive.
- Tumour-suppressor loss: brakes on proliferation or DNA damage response are removed.
- Repair-gene deficiency: mutation rate rises across the genome.
- Clonal evolution: treatment and the microenvironment select resistant subclones.
8. Clinical examples
Sickle-cell disease
A single missense variant in HBB changes beta-globin and promotes haemoglobin polymerisation under deoxygenated conditions. A patient may present with vaso-occlusive pain, acute chest syndrome, anaemia or stroke. Emergency care treats the acute complication while genetic counselling addresses inheritance and family planning.
Cystic fibrosis
Variants in CFTR alter chloride and bicarbonate transport. Different variants produce different residual function and phenotypes. Recurrent pulmonary infection, pancreatic insufficiency and salt-loss crises require coordinated care; a genotype does not replace clinical assessment.
Duchenne muscular dystrophy
Frameshift or nonsense variants in DMD can abolish dystrophin. Respiratory, cardiac and anaesthetic planning are important; avoid assuming a child’s weakness is simply behavioural or deconditioning.
Inherited cancer predisposition
A pathogenic germline variant in a tumour-suppressor or repair gene can increase lifetime cancer risk. A tumour result may be somatic only, so confirmatory germline testing and counselling are needed before informing relatives.
9. Clinical testing and variant interpretation
| Question | Useful approach | Caution |
|---|---|---|
| Single-gene disorder suspected | Targeted variant analysis or gene sequencing | A negative result may miss deep intronic, structural or mosaic changes |
| Multiple possible genes | Panel or exome sequencing | Variants of uncertain significance and incidental findings need counselling |
| Copy-number syndrome | Microarray or targeted deletion/duplication testing | Balanced rearrangements may be missed |
| Family variant known | Targeted testing for that variant | Confirm sample identity and consent |
| Tumour mutation | Somatic sequencing, FISH or cytogenetics | Does not automatically mean inherited risk |
Pathogenicity is assessed with population frequency, segregation in families, functional studies, computational predictions, conservation, case data and phenotype matching. Clinicians should not treat an uncertain variant as diagnostic without corroborating evidence.
10. Emergency medicine relevance
- Acute chest syndrome or vaso-occlusive crisis: treat hypoxia, pain, fever and respiratory compromise; do not delay emergency stabilisation while seeking genotype confirmation.
- Malignant hyperthermia susceptibility: a genetic predisposition may be known or suspected from family history; recognise hypercarbia, rigidity and hyperthermia rapidly and follow the emergency protocol.
- Inherited arrhythmia: a pathogenic channelopathy variant can explain syncope or sudden death in relatives; resuscitation and ECG management are immediate priorities.
- Severe drug reaction: pharmacogenetic risk may contribute, but stop the suspected drug and treat anaphylaxis, Stevens–Johnson syndrome or organ injury promptly.
- Newborn metabolic crisis: consider an inherited enzyme defect in unexplained hypoglycaemia, hyperammonaemia, acidosis or seizures, while providing glucose and supportive care.
11. Ethical and safety principles
- Obtain informed consent and explain the limits of testing.
- Protect confidentiality and consider implications for biological relatives.
- Do not use a genetic label to deny emergency treatment or make deterministic assumptions.
- Record drug reactions and confirmed pathogenic variants clearly in the medical record.
- Refer for genetic counselling when results affect reproduction, predictive testing or family screening.
12. Prevention and exposure control
Not all mutations are preventable. Risk reduction includes smoking cessation, occupational protection, ultraviolet protection, vaccination against oncogenic infections where indicated, safe handling of chemicals and ionising radiation, and avoiding unnecessary radiation exposure. These measures reduce acquired damage but do not eliminate inherited risk.
Quick self-test
- Why is “variant” often preferred to “mutation” in a laboratory report?
- Differentiate germline, somatic and mosaic variants.
- What is a frameshift and why is it often severe?
- Name two DNA-repair pathways and the lesions they correct.
- Why is a tumour variant not automatically an inherited mutation?
Answers
- Because a DNA change may be benign or of uncertain significance; “mutation” can imply disease.
- Germline changes can be inherited and are present in reproductive cells; somatic changes arise in body cells; mosaicism means genetically distinct cell lines coexist.
- An indel not divisible by three shifts the reading frame, changing downstream codons and often creating a premature stop.
- Base-excision repair corrects small damaged bases; nucleotide-excision repair removes bulky lesions such as UV dimers; mismatch repair corrects replication errors; homologous recombination repairs selected double-strand breaks.
- Most tumour variants arise only in cancer cells; germline testing is required to establish inherited risk.
References and further reading
- NCBI Bookshelf: DNA damage and repair.
- MedlinePlus Genetics: What is a gene mutation?.
- National Human Genome Research Institute genetics glossary.
- Use local laboratory, oncology, emergency and genetic-counselling protocols when interpreting or acting on variants.
